Work Here?
Industries
Healthcare
Company Size
51-200
Company Stage
Grant
Total Funding
$284.5M
Headquarters
San Jose, California
Founded
2012
Visby Medical provides rapid PCR tests for detecting infectious diseases, delivering results in under 30 minutes. This is a major advancement compared to traditional PCR tests that can take days for results. Their portable testing kits are designed for use in clinical and mobile laboratory settings, making them accessible and easy to deploy. Unlike conventional PCR equipment, which is large and complex, Visby's tests are compact and instrument-free, fitting in the palm of your hand. The company primarily serves healthcare providers in the United States, focusing on improving patient care by providing quick and accurate test results. By minimizing wait times, Visby aims to reduce patient callbacks and improve follow-up care. Their goal is to enhance the efficiency of infectious disease testing, addressing the growing demand for rapid and reliable diagnostics.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$284.5M
Above
Industry Average
Funded Over
6 Rounds
Health Insurance
Health Savings Account/Flexible Spending Account
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Visby Medical raised up to $65 million in a financing round led by Catalio Capital Management to accelerate the launch of its FDA-authorized at-home Women's Sexual Health Test. The funding will enhance market reach and operational capabilities. Isaac Ro from Catalio joins the board as an observer, and Chuck Alpuche joins as an independent director. The test, delivering results in 30 minutes, will be available from July 2025 through major direct-to-consumer channels.
Last month, Visby also acquired a 510(k) clearance from the FDA for its point-of-care respiratory disease test, designed to catch influenza A and B as well as the coronavirus behind COVID-19.
Visby Medical has secured an additional $3.9 million from CARB-X to enhance its PCR-based diagnostics for antibiotic resistance, building on a previous $1.2 million grant. The funding will aid in developing tools to detect resistance mutations in infections, starting with ciprofloxacin susceptibility in Neisseria gonorrhoeae. Visby aims to integrate these capabilities into its Sexual Health Test and develop a digital app for result interpretation.
SAN JOSE, Calif., Jan. 15, 2025 /PRNewswire/ - Visby Medical(TM), a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to accelerate its fight against antibiotic resistance.
The portable, instrument-free PCR test will be used to detect infections resistant to the frontline antibiotic ciprofloxacin and help reduce use of ceftriaxone.
Find jobs on Simplify and start your career today
Industries
Healthcare
Company Size
51-200
Company Stage
Grant
Total Funding
$284.5M
Headquarters
San Jose, California
Founded
2012
Find jobs on Simplify and start your career today